Compare Credo Technology Group Holding Ltd (CRDO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Novo Nordisk A/S — how do they compare? Credo Technology Group Holding Ltd trades at $267.74 (market cap $46.19B), while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 4.5× Credo Technology Group Holding Ltd's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| CRDO | NVO | |
|---|---|---|
Market Cap | $46.19B | $207.85B |
Sector | Technology | Health |
52-Week High | $302.52 | $63.98 |
52-Week Low | $87.81 | $35.29 |
Enterprise Value | $44.77B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $268.16, up 11.76% in 24 hours, with a bullish technical signal and strong institutional interest. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.16 exceeding expectations. Revenue surged to $436.78 million in 2025, and net income margin expanded to 35.37% in 2026. Positive news highlights Credo's role in AI infrastructure, including contributions to the Open Compute Project.
Outlook is positive due to AI-driven demand and strong financials, but risks include premium valuations (P/E 98.68) and customer concentration. Analyst consensus is bullish with a $285.42 price target. Investors should monitor execution risks and market volatility amid high growth expectations.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
